Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback